Maria Isabel Achatz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/906395/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene, 2007, 26, 2157-2165.	2.6	796
2	Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clinical Cancer Research, 2017, 23, e38-e45.	3.2	358
3	The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Letters, 2007, 245, 96-102.	3.2	170
4	Clinical Management and Tumor Surveillance Recommendations of Inherited Mismatch Repair Deficiency in Childhood. Clinical Cancer Research, 2017, 23, e32-e37.	3.2	157
5	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging. JAMA Oncology, 2017, 3, 1634.	3.4	148
6	Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li–Fraumeni syndrome. Current Opinion in Oncology, 2018, 30, 23-29.	1.1	129
7	<i>PTEN, DICER1, FH</i> , and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clinical Cancer Research, 2017, 23, e76-e82.	3.2	128
8	Gastric cancer in individuals with Li-Fraumeni syndrome. Genetics in Medicine, 2011, 13, 651-657.	1.1	118
9	Detailed haplotype analysis at the <i>TP53</i> locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Human Mutation, 2010, 31, 143-150.	1.1	116
10	Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Letters, 2008, 261, 21-25.	3.2	94
11	Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Current Opinion in Oncology, 2010, 22, 64-69.	1.1	91
12	Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood. Clinical Cancer Research, 2017, 23, e107-e114.	3.2	91
13	Brain tumors in individuals with familial adenomatous polyposis. Cancer, 2007, 109, 761-766.	2.0	88
14	Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups. Clinical Cancer Research, 2015, 21, 184-192.	3.2	84
15	Germline DNA copy number variation in familial and early-onset breast cancer. Breast Cancer Research, 2012, 14, R24.	2.2	76
16	Comprehensive Analysis of BRCA1, BRCA2 and TP53 Germline Mutation and Tumor Characterization: A Portrait of Early-Onset Breast Cancer in Brazil. PLoS ONE, 2013, 8, e57581.	1.1	70
17	Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening?. Lancet Oncology, The, 2009, 10, 920-925.	5.1	67
18	Variable population prevalence estimates of germline <i>TP53</i> variants: A gnomAD-based analysis. Human Mutation, 2019, 40, 97-105.	1.1	66

#	Article	IF	CITATIONS
19	TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. Journal of Medical Genetics, 2009, 46, 766-772.	1.5	64
20	The germline mutational landscape of BRCA1 and BRCA2 in Brazil. Scientific Reports, 2018, 8, 9188.	1.6	61
21	The Inherited p53 Mutation in the Brazilian Population. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026195.	2.9	60
22	Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients. BMC Medical Genetics, 2014, 15, 55.	2.1	57
23	Prevalence of the TP53 p.R337H Mutation in Breast Cancer Patients in Brazil. PLoS ONE, 2014, 9, e99893.	1.1	49
24	Higher-than-expected population prevalence of potentially pathogenic germline <i>TP53</i> variants in individuals unselected for cancer history. Human Mutation, 2017, 38, 1723-1730.	1.1	40
25	Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer. Annals of Surgical Oncology, 2015, 22, 971-978.	0.7	38
26	XAF1 as a modifier of p53 function and cancer susceptibility. Science Advances, 2020, 6, eaba3231.	4.7	37
27	A Common Molecular Mechanism Underlies Two Phenotypically Distinct 17p13.1 Microdeletion Syndromes. American Journal of Human Genetics, 2010, 87, 631-642.	2.6	36
28	Mutational spectrum of the APC and MUTYH genes and genotype–phenotype correlations in Brazilian FAP, AFAP, and MAP patients. Orphanet Journal of Rare Diseases, 2013, 8, 54.	1.2	35
29	TP53 mutation p.R337H in gastric cancer tissues of a 12-year-old male child - evidence for chimerism involving a common mutant founder haplotype: case report. BMC Cancer, 2011, 11, 449.	1.1	34
30	Genome-Wide DNA Methylation Analysis Reveals Epigenetic Dysregulation of MicroRNA-34A in <i>TP53</i> -Associated Cancer Susceptibility. Journal of Clinical Oncology, 2016, 34, 3697-3704.	0.8	33
31	Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanoma. Genetics in Medicine, 2016, 18, 727-736.	1.1	31
32	Whole-genome sequencing analysis of phenotypic heterogeneity and anticipation in Li–Fraumeni cancer predisposition syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15497-15501.	3.3	29
33	Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures. Carcinogenesis, 2014, 35, 807-815.	1.3	29
34	International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. Breast Cancer Research and Treatment, 2011, 127, 671-679.	1.1	27
35	Li-Fraumeni-like syndrome associated with a large BRCA1 intragenic deletion. BMC Cancer, 2012, 12, 237.	1.1	25
36	Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil. JCO Global Oncology, 2020, 6, 439-452.	0.8	25

#	Article	IF	CITATIONS
37	Molecular analysis of TSC1 and TSC2 genes and phenotypic correlations in Brazilian families with tuberous sclerosis. PLoS ONE, 2017, 12, e0185713.	1.1	24
38	Mouse Homolog of the Human <i>TP53</i> R337H Mutation Reveals Its Role in Tumorigenesis. Cancer Research, 2018, 78, 5375-5383.	0.4	24
39	Association of <i>TP53</i> polymorphisms on the risk of Wilms tumor. Pediatric Blood and Cancer, 2014, 61, 436-441.	0.8	23
40	Germline <i><scp>MLH</scp>1, <scp>MSH</scp>2</i> and <i><scp>MSH</scp>6</i> variants in Brazilian patients with colorectal cancer and clinical features suggestive of Lynch Syndrome. Cancer Medicine, 2018, 7, 2078-2088.	1.3	23
41	Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes. BMC Cancer, 2019, 19, 422.	1.1	22
42	Contribution of rare germline copy number variations and common susceptibility loci in Lynch syndrome patients negative for mutations in the mismatch repair genes. International Journal of Cancer, 2016, 138, 1928-1935.	2.3	21
43	Frequency of Thyroid Carcinoma in Brazilian <i>TP53 </i> p.R337H Carriers With Li Fraumeni Syndrome. JAMA Oncology, 2017, 3, 1400.	3.4	21
44	Complex Landscape of Germline Variants in Brazilian Patients With Hereditary and Early Onset Breast Cancer. Frontiers in Genetics, 2018, 9, 161.	1.1	21
45	Couples coping with screening burden and diagnostic uncertainty in Li-Fraumeni syndrome: Connection versus independence. Journal of Psychosocial Oncology, 2019, 37, 178-193.	0.6	21
46	Integration of Genomics in Cancer Care. Journal of Nursing Scholarship, 2013, 45, 43-51.	1.1	20
47	LINE-1 hypermethylation in peripheral blood of cutaneous melanoma patients is associated with metastasis. Melanoma Research, 2015, 25, 173-177.	0.6	20
48	Rare germline variant (rs78378222) in the TP53 3' UTR: Evidence for a new mechanism of cancer predisposition in Li-Fraumeni syndrome. Cancer Genetics, 2016, 209, 97-106.	0.2	19
49	Whole-body magnetic resonance imaging of Li-Fraumeni syndrome patients: observations from a two rounds screening of Brazilian patients. Cancer Imaging, 2018, 18, 27.	1.2	19
50	Germline CDKN2A mutations in Brazilian patients of hereditary cutaneous melanoma. Familial Cancer, 2014, 13, 645-649.	0.9	18
51	DNA Methylation Levels of Melanoma Risk Genes Are Associated with Clinical Characteristics of Melanoma Patients. BioMed Research International, 2015, 2015, 1-8.	0.9	17
52	Comprehensive germline mutation analysis and clinical profile in a large cohort of Brazilian xeroderma pigmentosum patients. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2392-2401.	1.3	17
53	Suggested application of HER2+ breast tumor phenotype for germline <i>TP53</i> variant classification within ACMG/AMP guidelines. Human Mutation, 2020, 41, 1555-1562.	1.1	16
54	Early-onset breast cancer patients in the South and Southeast of Brazil should be tested for the TP53 p.R337H mutation. Genetics and Molecular Biology, 2016, 39, 199-202.	0.6	15

#	Article	IF	CITATIONS
55	Screening for germline mutations in mismatch repair genes in patients with Lynch syndrome by next generation sequencing. Familial Cancer, 2018, 17, 387-394.	0.9	15
56	Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls. Genome Medicine, 2018, 10, 99.	3.6	15
57	Oral and maxillofacial considerations in Gardner's syndrome: a report of two cases. Ecancermedicalscience, 2016, 10, 623.	0.6	14
58	Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis. PLoS ONE, 2021, 16, e0247363.	1.1	14
59	18F-FDG PET-CT for Surveillance of Brazilian Patients with Li-Fraumeni Syndrome. Frontiers in Oncology, 2015, 5, 38.	1.3	13
60	CHEK2 1100DELC germline mutation: a frequency study in hereditary breast and colon cancer Brazilian families. Arquivos De Gastroenterologia, 2012, 49, 273-278.	0.3	12
61	The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations. Orphanet Journal of Rare Diseases, 2014, 9, 63.	1.2	12
62	The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score. International Journal of Gynecological Cancer, 2016, 26, 449-55.	1.2	12
63	p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers. Familial Cancer, 2018, 17, 269-274.	0.9	11
64	Reproductive factors associated with breast cancer risk in Li–Fraumeni syndrome. European Journal of Cancer, 2019, 116, 199-206.	1.3	10
65	Family Health Leaders: Lessons on Living with Liâ€Fraumeni Syndrome across Generations. Family Process, 2020, 59, 1648-1663.	1.4	10
66	Number of rare germline CNVs and TP53 mutation types. Orphanet Journal of Rare Diseases, 2012, 7, 101.	1.2	9
67	Xeroderma Pigmentosum: Low Prevalence of Germline XPA Mutations in a Brazilian XP Population. International Journal of Molecular Sciences, 2015, 16, 8988-8996.	1.8	9
68	Brazilian health-care policy for targeted oncology therapies and companion diagnostic testing. Lancet Oncology, The, 2016, 17, e363-e370.	5.1	9
69	ROBO1 deletion as a novel germline alteration in breast and colorectal cancer patients. Tumor Biology, 2016, 37, 3145-3153.	0.8	9
70	Haplotype analysis of the internationally distributed BRCA1 c.3331_334delCAAG founder mutation reveals a common ancestral origin in Iberia. Breast Cancer Research, 2020, 22, 108.	2.2	9
71	The breast cancer immunophenotype of TP53-p.R337H carriers is different from that observed among other pathogenic TP53 mutation carriers. Familial Cancer, 2015, 14, 333-336.	0.9	8
72	Role of rare germline copy number variation in melanoma-prone patients. Future Oncology, 2016, 12, 1345-1357.	1.1	8

#	Article	IF	CITATIONS
73	Rare germline alterations in cancer-related genes associated with the risk of multiple primary tumor development. Journal of Molecular Medicine, 2017, 95, 523-533.	1.7	8
74	Pheochromocytoma and paraganglioma: implications of germline mutation investigation for treatment, screening, and surveillance. Archives of Endocrinology and Metabolism, 2019, 63, 369-375.	0.3	8
75	Ancestry of the Brazilian TP53 c.1010G>A (p.Arg337His, R337H) Founder Mutation: Clues from Haplotyping of Short Tandem Repeats on Chromosome 17p. PLoS ONE, 2015, 10, e0143262.	1.1	8
76	Breast Cancer Phenotype Associated With Li-Fraumeni Syndrome: A Brazilian Cohort Enriched by TP53 p.R337H Carriers. Frontiers in Oncology, 2022, 12, 836937.	1.3	8
77	Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 927-935.	1.1	7
78	Identification of the <i>TP53</i> p.R337H Variant in Tumor Genomic Profiling Should Prompt Consideration of Germline Testing for Li-Fraumeni Syndrome. JCO Global Oncology, 2021, 7, 1141-1150.	0.8	7
79	A Set of miRNAs, Their Gene and Protein Targets and Stromal Genes Distinguish Early from Late Onset ER Positive Breast Cancer. PLoS ONE, 2016, 11, e0154325.	1.1	7
80	<i>HABP2</i> p.G534E variant in patients with family history of thyroid and breast cancer. Oncotarget, 2017, 8, 40896-40905.	0.8	7
81	DNA methylation patterns of candidate genes regulated by thymine DNA glycosylase in patients with TP53 germline mutations. Brazilian Journal of Medical and Biological Research, 2015, 48, 610-615.	0.7	6
82	Genome-wide DNA methylation profile of leukocytes from melanoma patients with and without CDKN2A mutations. Experimental and Molecular Pathology, 2014, 97, 425-432.	0.9	5
83	Genomic profile of a Li-Fraumeni-like syndrome patient with a 45,X/46,XX karyotype, presenting neither mutations in TP53 nor clinical stigmata of Turner syndrome. Cancer Genetics, 2015, 208, 341-344.	0.2	5
84	MIR605 rs2043556 is associated with the occurrence of multiple primary tumors in TP53 p.(Arg337His) mutation carriers. Cancer Genetics, 2020, 240, 54-58.	0.2	5
85	Complete Clinical Response in Stage IVB Endometrioid Endometrial Carcinoma after First-Line Pembrolizumab Therapy: Report of a Case with Isolated Loss of PMS2 Protein. Case Reports in Oncology, 2021, 13, 1067-1074.	0.3	5
86	Does germ-line deletion of the PIP gene constitute a widespread risk for cancer?. European Journal of Human Genetics, 2014, 22, 307-309.	1.4	4
87	Testing Positive on a Multigene Panel Does Not Suffice to Determine Disease Risks. Journal of the National Cancer Institute, 2018, 110, 797-798.	3.0	4
88	Germline BAX Deletion in a Patient With Melanoma and Gastrointestinal Stromal Tumor. American Journal of Gastroenterology, 2013, 108, 1372-1375.	0.2	3
89	Primary versus interval debulking surgery and the risk to induce platinum resitance Journal of Clinical Oncology, 2014, 32, 5588-5588.	0.8	3
90	Germline Mutation in MUS81 Resulting in Impaired Protein Stability is Associated with Familial Breast and Thyroid Cancer. Cancers, 2020, 12, 1289.	1.7	3

#	Article	IF	CITATIONS
91	Genomic Alterations in Patients Showing Multiple Primary Tumors and Family History of Cancer. Annals of Oncology, 2014, 25, iv165.	0.6	2
92	Germline large genomic alterations on 7q in patients with multiple primary cancers. Scientific Reports, 2017, 7, 41677.	1.6	2
93	Early-Onset Colorectal Cancer in Patients with Li Fraumeni Syndrome: Is It Really Enough to Justify Early Colon Cancer Screening?. Gastroenterology, 2019, 157, 264.	0.6	2
94	Prevalence of the Brazilian TP53 Founder c.1010G>A (p.Arg337His) in Lung Adenocarcinoma: Is Genotyping Warranted in All Brazilian Patients?. Frontiers in Genetics, 2021, 12, 606537.	1.1	2
95	Keratocystic odontogenic tumor related to nevoid basal cell carcinoma syndrome: clinicopathological study. Brazilian Journal of Oral Sciences, 2013, 12, 23-29.	0.1	2
96	Evaluation of rapid whole-body magnetic resonance as screening strategy for early cancer detection in 57 Brazilian Li-Fraumeni syndrome patients Journal of Clinical Oncology, 2015, 33, 1534-1534.	0.8	2
97	Abstract A37: Complex landscape of germline variants in hereditary and early-onset breast cancer ascertained through whole exome sequencing. , 2018, , .		2
98	Response to "Germline TP53 R337H mutation is not sufficient to establish Li-Fraumeni or Li-Fraumeni-like syndromeâ€ , by Ribeiro et al Cancer Letters, 2007, 247, 356-358.	3.2	1
99	Li-Fraumeni Ontology: A Case Study of an Ontology for Knowledge Discovery in a Cancer Domain. , 2015, , .		1
100	Response to: Concern regarding classification of germline TP53 variants as likely pathogenic. Human Mutation, 2019, 40, 832-833.	1.1	1
101	Utility of interim blood tests for cancer screening in Li-Fraumeni syndrome. Familial Cancer, 2022, 21, 333-336.	0.9	1
102	Expanding the phenotype of E318K (c.952G > A) MITF germline mutation carriers: case series and review of the literature. Hereditary Cancer in Clinical Practice, 2021, 19, 32.	0.6	1
103	Molecular Analyses of Early-Onset Gastric Cancer in Brazilian Patients: <i>TP</i> 53 Mutations, Cadherin-Catenin and Mucins Proteins Expression. Journal of Cancer Therapy, 2013, 04, 33-42.	0.1	1
104	Homologous recombination deficiency and platinum rechallenge in platinum-resistant ovarian cancer patients Journal of Clinical Oncology, 2017, 35, 5576-5576.	0.8	1
105	Effect of breastfeeding on the risk of breast cancer in Li-Fraumeni syndrome Journal of Clinical Oncology, 2018, 36, 1530-1530.	0.8	1
106	Abstract P6-08-18: Breast cancer in Li-Fraumeni syndrome and risk-reduction mastectomy inTP53p.R337H carriers. , 2020, , .		1
107	Novel Insights From the Germline Landscape of Breast Cancer in Brazil. Frontiers in Oncology, 2021, 11, 743231.	1.3	1
108	Cancer surveillance for patients with Li-Fraumeni Syndrome in Brazil: A cost-effectiveness analysis. The Lancet Regional Health Americas, 2022, 12, 100265.	1.5	1

#	Article	IF	CITATIONS
109	3311 Germline mutations and rare copy number variations in melanoma-prone patients. European Journal of Cancer, 2015, 51, S668.	1.3	0
110	Genomic profile of Li-Fraumeni syndrome patients with adrenocortical carcinoma in childhood. Annals of Oncology, 2016, 27, vi11.	0.6	0
111	Commentary regarding Schayek et al., entitled "The rate of recurrent BRCA1, BRCA2, and TP53 mutations in the general population, and unselected ovarian cancer cases, in Belo Horizonte, Brazil― Cancer Genetics, 2016, 209, 282-283.	0.2	0
112	CN4 Duty to recontact patients previously tested with negative results in a hereditary cancer syndrome center. Annals of Oncology, 2020, 31, S1123-S1124.	0.6	0
113	Inherited Pediatric Cancer in Low- and Intermediate-Resource Countries. , 2021, , 361-386.		0
114	Differential Gene Expression Profiles in Breast Cancer Tumors from Young and Post-Menopausal Patients , 2009, , .		0
115	Abstract 3038: Determination of microRNA expression profile in tumors from young women with breast cancer. , 2010, , .		0
116	Abstract 1836: Distinct tumor spectrum and age of onset in a Brazilian cohort of p.R337HTP53mutation carriers. , 2011, , .		0
117	Abstract 5598: Germline TP53 mutation in very early onset breast cancer patients without BRCA1 and BRCA2 mutation in Brazilian population. , 2011, , .		0
118	Abstract 1837: Clinical diversity and tumor spectrum in Xeroderma Pigmentosum Brazilian patients. , 2011, , .		0
119	Abstract LB-329: Copy number variations associated with hereditary breast and colorectal carcinomas. , 2011, , .		0
120	Abstract B10: Germline copy number variation in Li-Fraumeni syndrome patients with TP53 mutations. , 2011, , .		0
121	Abstract A24: Germline deletion at 3p12.3 in patients with hereditary breast and colorectal carcinoma. , 2011, , .		0
122	P1-09-07: Contribution of TP53 p.R337H Mutation to Breast Cancer Incidence in Brazil , 2011, , .		0
123	Abstract 5349: Cancer stem cells isolation and characterization from breast tumor of a germline carrier of TP53 p.R337H (Brazilian founder) mutation. , 2012, , .		0
124	Abstract 3771: Establishment of primary cultures of cancer stem cells from patients with Li-Fraumeni Syndrome, carrier of TP53 p.R337H Brazilian founder mutation , 2013, , .		0
125	Abstract A025: Screening for genomic rearrangements and germline mutations in BRCA1 and BRCA2 genes in hereditary breast cancer unrelated Brazilian families. , 2013, , .		0
126	Identification of a rare germ-line variant in the <i>TP53</i> 3'UTR in individuals with the Li-Fraumeni-like phenotype: A new mechanism of cancer predisposition?. Journal of Clinical Oncology, 2014, 32, 11106-11106.	0.8	0

#	Article	IF	CITATIONS
127	Abstract 3418: Rare germline copy number variations in hereditary cutaneous melanoma. , 2014, , .		0
128	Molecular and clinical profile of Li-Fraumeni Syndrome in a Brazilian cohort Journal of Clinical Oncology, 2015, 33, e12533-e12533.	0.8	0
129	Abstract 2751: Identification of predisposition genes involved in thyroid and breast carcinomas in patients with family history of these tumors by whole exome sequencing. , 2015, , .		0
130	Abstract 2753: The germline TP53 p.R337H mutation: a putative selective advantage. , 2015, , .		0
131	Prevalence of germline <i>TP53</i> p.R337H mutation in Brazilian young breast cancer patients Journal of Clinical Oncology, 2017, 35, e13101-e13101.	0.8	0
132	Abstract 4287:HABP2p.G534E variant in patients with family history of thyroid and breast cancer. , 2017, , .		0
133	Abstract 4282: GermlineTP53p.R337H mutations and Li-Fraumeni syndrome: A new variant form of the disease. , 2017, , .		0
134	Abstract NG05: TP53-mediated human cancer susceptibility is defined by epigenetic dysregulation of microRNA-34A. , 2017, , .		0
135	Abstract A20: Identification of new promising germline variants in melanoma-prone patients. , 2018, , .		0
136	Abstract 1247: Hereditary paraganglioma-pheochromocytoma syndrome: Patterns of presentation in a Brazilian oncogenetics clinic. , 2018, , .		0
137	Abstract 3316: Screening blood tests and cancer detection in Li-Fraumeni syndrome. , 2019, , .		0